ClearSkin
Microbiomic Treatment for Psoriasis and Other Skin Conditions
Company Overview
Snapshot
Founded in May 2017 by Milana Shternberg and Veronika Loiferman, ClearSkin operates with 1–10 employees. The company has developed and launched MiBiome, a first-generation product focused on the dermal microbiome to treat various skin conditions.
Business overview
ClearSkin Medical specializes in developing innovative treatments for skin diseases within the Health Tech & Life Sciences sector. The company's core product, MiBiome, is an all-natural formulation utilizing a probiotic complex to soothe and rebalance the skin's ecosystem. ClearSkin targets markets dealing with chronic skin conditions such as psoriasis, atopic dermatitis, eczema, urticaria, and general itching, serving both B2C and B2B segments.
Company Intelligence Q&A
- What is ClearSkin's primary focus?
- ClearSkin's primary focus is on developing innovative treatments for skin diseases, particularly those related to the dermal microbiome.
- What is MiBiome?
- MiBiome is ClearSkin's first-generation product, an all-natural formulation with a probiotic complex designed to soothe and rebalance the skin's ecosystem for treating conditions like psoriasis, atopic dermatitis, and eczema.
- When was ClearSkin founded?
- ClearSkin was founded in May 2017.
- Who are the founders of ClearSkin?
- ClearSkin was founded by Milana Shternberg, who serves as CEO, and Veronika Loiferman, who serves as COO.
- Which markets does ClearSkin serve?
- ClearSkin serves markets dealing with chronic skin conditions, including psoriasis, atopic dermatitis, eczema, urticaria, and itching, operating in both B2C and B2B models.